検索結果

Product Development Policy | Research & Development | SENJU Pharmaceutica

etina, cause bleeding and edema. In recent drug therapies, intravitreal injection of antibody drugs targeting the vascular endothelial growth factor (VEGF) protein, which increases angiogenesis and le...

administration trial demonstrated positive results confirming the safety of clinical use. DED, the target disease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tea...

s first successful clinical development of a TRPV1 antagonist for DED, completed in Japan. DED, the target disease of Avarept®, is defined as “A multifactorial disease characterized by an unstable tea...

iod required for regulatory approval, resulting in early approval and launch. CRAO, the therapeutic target of SJP-0008, occurs when central retinal artery occlusion leads to irreversible impairment of...

ound having the development code SJP-0008. Central Retinal Artery Occlusion (CRAO), the therapeutic target of SJP-0008, occurs when central retinal artery occlusion leads to irreversible impairment of...